The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A member of the class of benzimidazoles that is benzimidalole which is substituted at position 2 by a (methoxycarbonyl)amino group and at position 5 by a 2-thienoyl group. It is an antineoplastic agent that exerts its effect by depolymerising microtubules.
Nocodazole results in increased expression of ACTA2 mRNA 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Nocodazole results in increased expression of ACTA2 mRNA]
Nocodazole inhibits the reaction [Dihydrotestosterone results in increased localization of AR protein] Nocodazole results in decreased localization of AR protein
Doxorubicin inhibits the reaction [Nocodazole inhibits the reaction [Hydroxyurea results in increased phosphorylation of ATM protein]]; Nocodazole inhibits the reaction [Hydroxyurea results in increased phosphorylation of ATM protein]
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased expression of and results in increased phosphorylation of AURKA protein; [bisphenol A analog co-treated with Nocodazole] results in decreased expression of AURKA protein; [bisphenol A co-treated with Nocodazole] results in decreased expression of AURKA protein; MLN8054 inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased phosphorylation of AURKA protein]
4-(4-(N-benzoylamino)anilino)-6-methoxy-7-(3-(1-morpholino)propoxy)quinazoline inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased phosphorylation of AURKB protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased phosphorylation of AURKB protein
Nocodazole results in increased phosphorylation of BCL2 protein TYMP inhibits the reaction [Nocodazole results in increased phosphorylation of BCL2 protein] Nocodazole analog results in decreased expression of BCL2 protein
[Nocodazole co-treated with Caffeine] results in increased expression of BUB1 protein modified form; chromium hexavalent ion inhibits the reaction [Nocodazole results in increased phosphorylation of BUB1 protein]
Nocodazole results in increased cleavage of CASP3 protein Nocodazole analog results in decreased expression of CASP3 protein [Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein; [Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein; Caffeine promotes the reaction [[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein]; NOTCH1 protein mutant form inhibits the reaction [Caffeine promotes the reaction [[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein]]
Caspase Inhibitors inhibits the reaction [Nocodazole analog results in increased expression of CASP8 protein modified form] Nocodazole analog results in increased cleavage of CASP8 protein
Nocodazole inhibits the reaction [sodium arsenite affects the localization of CCAR1 protein]; Nocodazole promotes the reaction [CCAR1 protein binds to ANAPC2 protein] Nocodazole results in increased expression of CCAR1 protein
Nocodazole affects the localization of CFTR protein Nocodazole inhibits the reaction [Cyclic AMP affects the localization of and results in increased activity of CFTR protein]
Nocodazole inhibits the reaction [kaempferol results in increased secretion of CSF2 protein]; Nocodazole inhibits the reaction [Quercetin results in increased secretion of CSF2 protein]
Nocodazole inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Nocodazole inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Nocodazole inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein] Nocodazole inhibits the reaction [benzotriphenylene results in increased expression of and results in increased activity of CYP1A1 protein]; Nocodazole inhibits the reaction [benzotriphenylene results in increased expression of CYP1A1 mRNA]
[TYMP co-treated with Nocodazole] results in decreased expression of FASLG mRNA; [TYMP co-treated with Nocodazole] results in decreased expression of FASLG protein
Nocodazole inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Nocodazole inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]
Nocodazole results in increased phosphorylation of JUN protein TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of JUN protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein; TYMP affects the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein]; U 0126 inhibits the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein] Nocodazole inhibits the reaction [NGF protein results in increased activity of MAPK1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein; TYMP affects the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein]; U 0126 inhibits the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein] Nocodazole inhibits the reaction [NGF protein results in increased activity of MAPK3 protein]
Nocodazole results in increased phosphorylation of MAPK9 protein TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of MAPK9 protein]
Nocodazole inhibits the reaction [NGF protein affects the localization of NTRK1 protein]; Nocodazole inhibits the reaction [NGF protein affects the localization of RAP1A protein]; Nocodazole inhibits the reaction [NGF protein results in increased activity of MAPK1 protein]; Nocodazole inhibits the reaction [NGF protein results in increased activity of MAPK3 protein]; Nocodazole inhibits the reaction [NGF protein results in increased activity of RAP1A protein]
Nocodazole results in decreased expression of NOTCH1 protein BI 2536 inhibits the reaction [Nocodazole results in decreased expression of NOTCH1 protein]; Doxorubicin inhibits the reaction [Nocodazole promotes the reaction [Hydroxyurea results in decreased expression of NOTCH1 protein]]; Nocodazole promotes the reaction [Hydroxyurea results in decreased expression of NOTCH1 protein]; NOTCH1 protein mutant form inhibits the reaction [Caffeine promotes the reaction [[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein]]
TYMP inhibits the reaction [Nocodazole results in increased cleavage of PARP1 protein] Nocodazole analog results in increased cleavage of PARP1 protein; Nocodazole results in increased cleavage of PARP1 protein
[Hydroxyurea co-treated with Nocodazole] affects the expression of and affects the phosphorylation of PLK1 protein; Doxorubicin affects the reaction [[Hydroxyurea co-treated with Nocodazole] affects the expression of and affects the phosphorylation of PLK1 protein] Nocodazole results in decreased phosphorylation of PLK1 protein
Nocodazole inhibits the reaction [NGF protein affects the localization of RAP1A protein]; Nocodazole inhibits the reaction [NGF protein results in increased activity of RAP1A protein]
Nocodazole inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Nocodazole inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of JUN protein]; TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of MAPK8 protein]; TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of MAPK9 protein] Nocodazole analog results in increased expression of TP53 protein; Nocodazole results in increased expression of TP53 protein
[TYMP co-treated with Nocodazole] results in decreased expression of FASLG mRNA; [TYMP co-treated with Nocodazole] results in decreased expression of FASLG protein; TYMP affects the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein]; TYMP affects the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein]; TYMP inhibits the reaction [Nocodazole results in increased cleavage of PARP1 protein]; TYMP inhibits the reaction [Nocodazole results in increased phosphorylation of BCL2 protein]
browse the term
